Leerink raised the firm’s price target on Cogent Biosciences (COGT) to $18 from $16 and keeps an Outperform rating on the share after the company reported topline results from SUMMIT Part 2, the pivotal trial of bezuclastinib in indolent systemic mastocytosis. While the efficacy on a placebo-adjusted rate was in line with the firm’s expectations, safety was better than anticipated, positioning the stock well for the APEX and PEAK readouts in the second half of 2025 and year-end 2025, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target raised at Jefferies after ‘home run’ data
- Cogent Biosciences trading resumes
- Cogent Biosciences trading halted, volatility trading pause
- Morning Movers: WNS Holdings jumps following deal to be bought by Capgemini
- Cogent Biosciences Announces Positive SUMMIT Trial Results